Oruka Therapeutics’ (ORKA) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report issued on Friday,RTT News reports. Wedbush currently has a $40.00 price target on the stock.

A number of other research analysts also recently weighed in on ORKA. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Buy” and a consensus target price of $39.86.

Oruka Therapeutics Stock Performance

ORKA stock opened at $10.46 on Friday. The stock has a market capitalization of $366.09 million, a PE ratio of -1.67 and a beta of 0.67. The stock has a fifty day simple moving average of $13.26. Oruka Therapeutics has a 1-year low of $9.44 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.19. As a group, equities research analysts forecast that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the stock in a transaction dated Friday, February 14th. The shares were purchased at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now owns 4,148,428 shares in the company, valued at $47,458,016.32. This represents a 2.19 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased 98,339 shares of company stock valued at $1,128,456 over the last three months. Company insiders own 22.67% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the company. FMR LLC bought a new position in Oruka Therapeutics in the 3rd quarter valued at $114,763,000. RTW Investments LP bought a new stake in Oruka Therapeutics during the third quarter valued at $45,359,000. Vanguard Group Inc. boosted its stake in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after buying an additional 1,572,853 shares during the period. Price T Rowe Associates Inc. MD grew its position in Oruka Therapeutics by 374.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company’s stock worth $25,730,000 after buying an additional 1,047,245 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth about $17,661,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.